Compare Neurocrine Biosciences Inc (NBIX) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Sprott Uranium Miners ETF — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Sprott Uranium Miners ETF trades at $56.07. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | URNM | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $185.50 | $83.99 |
52-Week Low | $123.10 | $47.13 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
URNM, the Sprott Uranium Miners ETF, trades at $57.38, up 0.54% on the day, with a neutral technical signal. Key support lies at $57 and resistance at $58. The ETF offers concentrated exposure to uranium miners, benefiting from long-term supply deficits and rising demand driven by nuclear energy adoption for AI power needs. Recent news highlights strong fundamentals, including government funding and tech company reactor deals.
Outlook remains positive due to structural uranium supply shortages and increasing nuclear energy demand, though volatility risks persist from price swings and geopolitical factors. Analyst sentiment is mixed, with some advocating pure-miner exposure for higher upside, while others caution on valuation divergences from spot uranium prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
